COMMUNIQUÉS West-GlobeNewswire

Caladrius Biosciences to Host 2019 First Quarter Financial Results Conference Call on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time
02/05/2019
BASKING RIDGE, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the [...]
Novo Nordisk A/S: Share repurchase programme
02/05/2019
Bagsværd, Denmark, 2 May 2019 - On 1 February 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
XBiotech Announces Enrollment Completion, Positive Findings for Bermekimab in Pancreatic Cancer Study
02/05/2019
XBiotech and Cedars-Sinai Medical Center Evaluate Bermekimab in Combination with Chemotherapy in Patients with Pancreatic Cancer and Cachexia AUSTIN, Texas, May 02, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) [...]
Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019
02/05/2019
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a [...]
EDAP TMS SA to Announce First Quarter 2019 Financial Results on Wednesday, May 15, 2019
02/05/2019
Company to host conference call and webcast on Thursday, May 16, at 8:30 am EDT LYON, France, May 2, 2019 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release [...]
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business Updates
02/05/2019
CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs [...]
Neos Therapeutics to Host First Quarter 2019 Financial and Operating Results Conference Call on May 9th, 2019
02/05/2019
DALLAS and FORT WORTH, Texas, May 02, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) [...]
IntelGenx to Report First Quarter 2019 Financial Results on May 9, 2019 – Conference Call to Follow
02/05/2019
SAINT LAURENT, Quebec, May 02, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its first quarter 2019 financial results after market close on May [...]
MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
02/05/2019
SOUTH SAN FRANCISCO, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious [...]
CytomX Therapeutics to Announce First Quarter 2019 Financial Results
02/05/2019
-Teleconference Scheduled for May 9, 2019, at 5:00 p.m. ET- SOUTH SAN FRANCISCO, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical [...]
Homology Medicines Presents Data from Gene Therapy and Gene Editing Programs and Manufacturing Capabilities at ASGCT Meeting
02/05/2019
- Homology’s Scalable HEK293 Suspension Manufacturing Process for AAVHSCs Demonstrated Superiority to a Baculovirus System and AAVHSC15 Showed Improved In Vivo Efficacy Compared to AAV5 in PKU Model - - Non-clinical [...]
CareDx Adds iBox Technology, Next Step Towards Artificial Intelligence in Transplant Care
02/05/2019
CareDx collaboration with Cibiltech provides prognostic information on allograft survival BRISBANE, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the [...]
Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019
02/05/2019
MORRIS PLAINS, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today [...]
Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis
02/05/2019
Pivotal STRIDES trials to be conducted to support lorecivivint as a potential disease-modifying treatment for knee osteoarthritis First patient dosing is anticipated in the second quarter of 2019 SAN DIEGO, May 02, 2019 [...]
PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019
02/05/2019
MALVERN, Pa. and SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies [...]
Chipmunk Health chooses Philips HealthSuite digital platform to roll out and scale up its telehealth services
02/05/2019
May 1, 2019 Powered by Philips’ HealthSuite digital platform, new General Practitioner telehealth service from Chipmunk Health aims to forge a closer and more effective relationship between patients and their doctors [...]
Release date of three-month interim report 2019 for ALK and audio cast
02/05/2019
On Thursday, 9 May 2019, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) releases its three-month interim report 2019. ALK will host a meeting for analysts and institutional investors that day at 13.30 p.m. (CEST) at which [...]
So-Young Announces Pricing of Initial Public Offering
02/05/2019
BEIJING, May 02, 2019 (GLOBE NEWSWIRE) -- So-Young International Inc. (NASDAQ: SY) (“So-Young” or the “Company”), the most popular online destination for discovering, evaluating and reserving medical aesthetic services [...]
LIDDS develops its own proprietary product for intratumoral immunotherapy - Freedom to operate analysis done for the TLR9-agonist project
02/05/2019
LIDDS has an ongoing preclinical development program based on a clinical stage TLR9 agonist. The objective is to use a NanoZolid® formulation with the TLR9 agonist as an intratumoral immunotherapy in combination with [...]

Pages